Investigating how miR-152 affects breast cancer treatment response
MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response
This study is looking at how a molecule called miR-152 affects triple negative breast cancer, which often doesn't respond well to common treatments, to help find better ways to treat patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11061393 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a specific molecule, miR-152, in breast cancer, particularly in triple negative breast cancer (TNBC), which is known for its resistance to treatments like doxorubicin and radiation. The researchers aim to uncover how lower levels of miR-152 contribute to treatment resistance and explore its potential targets, including PKM2 and SLC7A5, which may influence cancer cell metabolism and growth. By identifying these mechanisms, the study seeks to improve treatment strategies for patients with TNBC. Patients may benefit from insights that could lead to more effective therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple negative breast cancer who are undergoing treatment.
Not a fit: Patients with non-triple negative breast cancer types may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with triple negative breast cancer, enhancing their chances of survival.
How similar studies have performed: Previous research has shown promising results in targeting similar molecular pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: He, Jun — Thomas Jefferson University
- Study coordinator: He, Jun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.